Diagnosis & Disease Information

Nab-Paclitaxel Plus Gemcitabine Improves Survival in Metastatic Pancreatic Adenocarcinoma

Weekly nanoparticle albumin-bound (nab)-paclitaxel plus gemcitabine significantly improved survival in patients with metastatic adenocarcinoma of the pancreas compared with gemcitabine alone, results of a global phase 3 trial reported in advance of being presented during the 10th annual Gastrointestinal Cancers Symposium on January 25th in San Francisco, CA.

Next post in Endocrine Cancer